Across
- 2. Strategy for choosing the right AD therapy at the right time
- 4. Hydrogel studied in a phase 2b trial for mild to moderate AD
- 7. Brand of microbiome-friendly lotion for AD
- 9. Acronym for a conference offering deep dives into AD care
- 10. Commonly disrupted by night-time itching in patients with AD
- 11. Janus kinase inhibitor shown to relieve ad symptoms faster than dupilumab
- 12. Poly-l-lysine biovectors were combined with these for AD efficacy
- 13. Describes the psychosocial and physical weight of chronic AD
Down
- 1. Underlying process targeted by many AD therapies
- 3. Clinical term for the hallmark symptom of AD
- 5. Topical JAK inhibitor evaluated for use in children aged 2–11
- 6. Aryl hydrocarbon receptor agonist with lasting effects in AD
- 8. IL-4 receptor blocker commonly used in moderate to severe AD